Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)
Juno's Investigational CAR T Cell Product Candidate JCAR014 Demonstrates Encouraging Clinical Responses And Translational Insights In Patients With B-Cell Cancers

Juno's Investigational CAR T Cell Product Candidate JCAR014 Demonstrates Encouraging Clinical Responses And Translational Insights In Patients With B-Cell Cancers

Data Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Juno's Investigational CAR T Cell Product Candidate JCAR015 Demonstrates Encouraging Clinical Responses In Patients With B-Cell Cancers

Juno's Investigational CAR T Cell Product Candidate JCAR015 Demonstrates Encouraging Clinical Responses In Patients With B-Cell Cancers

-- Data Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting --

Juno Therapeutics Appoints Dr. Hyam I. Levitsky As Chief Scientific Officer

Juno Therapeutics Appoints Dr. Hyam I. Levitsky As Chief Scientific Officer

Addition Strengthens Leadership Team and Supports Continued Advancement and Expansion of Immunotherapy Pipeline

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care.

'Mad Money' Lightning Round: Buy, Buy, Buy Dunkin Brands

'Mad Money' Lightning Round: Buy, Buy, Buy Dunkin Brands

Cramer is a big fan of Bristol-Myers, says American Tower is a bargain and prefers Red Hat over Hortonworks.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be watching earnings from retailers Urban Outfitters, Home Depot and Wal-Mart.

Juno Therapeutics (JUNO) Stock Gains in After-Hours Trading Following Earnings Release

Juno Therapeutics (JUNO) Stock Gains in After-Hours Trading Following Earnings Release

Juno Therapeutics (JUNO) shares are rising after the company beat analysts first quarter net loss expectations.

Should You Buy Bonds or Sell Them Ahead of a Potential Rate Hike?

Should You Buy Bonds or Sell Them Ahead of a Potential Rate Hike?

The CNBC 'Fast Money' traders discuss bonds and utility stocks ahead of the potential interest rate hike, while also looking ahead to next week's earnings results.

Juno Therapeutics (JUNO) Stock Falls Today on Mediocre Solid Tumor Therapy Data

Juno Therapeutics (JUNO) Stock Falls Today on Mediocre Solid Tumor Therapy Data

Shares of Juno Therapeutics (JUNO) were down in late morning trading Monday after so-called CAR-T cellular therapies for solid tumors showed mediocre results at a conference on Sunday.

CAR-T Therapy Stocks Fall Following Cancer Research Meeting

CAR-T Therapy Stocks Fall Following Cancer Research Meeting

The shares of a number of companies that are developing CAR-T cancer therapies are falling following the annual meeting of the American Association for Cancer Research.

Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data

Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data

Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.

Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors

Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors

The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.

Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched

Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched

The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.

'Mad Money' Lightning Round: I'm No Fan of World Wrestling Entertainment

'Mad Money' Lightning Round: I'm No Fan of World Wrestling Entertainment

Cramer is staying away from Juno Therapeutics and Foundation Medicine.

Jim Cramer's 'Mad Money' Recap: Weak Unemployment Is Good for Stocks

Jim Cramer's 'Mad Money' Recap: Weak Unemployment Is Good for Stocks

It's time to accept the fact the futures are often wrong, Cramer says.

Young Investors Should Hope for a Pullback Sooner Rather Than Later

Young Investors Should Hope for a Pullback Sooner Rather Than Later

The CNBC 'Fast Money Halftime' traders discuss attributes young investors should look to develop for the markets, while a market pro weighs in with his top picks.

Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro

Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro

Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene

Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

There's Action Below the Surface

Biotechs are still bubbly in 'stock pickers' market.

Bears Shouldn't Get Too Cocky

There's still plenty of action out there.